Clinical Trials at Smilow Cancer Hospital Care Center at Glastonbury
As of August 2026, 29 paid clinical trials are recruiting at Smilow Cancer Hospital Care Center at Glastonbury in Glastonbury, Connecticut. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer and Stage IV Lung Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
29 clinical trials at Smilow Cancer Hospital Care Center at Glastonbury
·Clear filters·Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
ATEMPT 2.0: Adjuvant T-DM1 vs TH
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Common conditions studied in Glastonbury
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Breast Cancer (4 active studies)
- Stage IV Lung Cancer AJCC v8 (4 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Glastonbury
- SWOG Cancer Research Network
- National Cancer Institute (NCI)
- NRG Oncology
- ECOG-ACRIN Cancer Research Group
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Glastonbury?
There are approximately 34 recruiting clinical trials in Glastonbury, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Glastonbury pay participants?
Most recruiting trials in Glastonbury compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Glastonbury?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Glastonbury?
The most common conditions under active study in Glastonbury include Anatomic Stage II Breast Cancer AJCC v8 (4), Breast Cancer (4), Stage IV Lung Cancer AJCC v8 (4), Recurrent Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Glastonbury?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Glastonbury on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Glastonbury?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Glastonbury?
Recruiting research sites in Glastonbury include Smilow Cancer Hospital Care Center at Glastonbury, Smilow Cancer Hospital - Glastonbury, Smilow Cancer Hospital at Glastonbury, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Glastonbury right now?
The largest active categories in Glastonbury are Cancer & tumors (31). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.